<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04560101</url>
  </required_header>
  <id_info>
    <org_study_id>5491</org_study_id>
    <nct_id>NCT04560101</nct_id>
  </id_info>
  <brief_title>Motor and Non-motor Symptoms in Cervical Dystonia</brief_title>
  <acronym>Royal</acronym>
  <official_title>Motor and Non-motor Symptoms in Patients With Cervical Dystonia and the Effect of Treatment With Botulinum Toxin A</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Roma La Sapienza</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ipsen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Roma La Sapienza</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this monocenter, observational, non-interventional, prospective, open label study&#xD;
      investigators will enrol 43 CD patients from the outpatient Movement Disorders Clinic of the&#xD;
      Department of Human Neurosciences, Sapienza University of Rome.&#xD;
&#xD;
      As this is a non-interventional study, no diagnostic, therapeutic or experimental&#xD;
      intervention is involved. Subjects will receive clinical assessments, medications and&#xD;
      treatments solely as determined by their study physician. The BoNT-A injection will be&#xD;
      performed in CD patients at baseline.&#xD;
&#xD;
      As this is an observational, non-interventional study, the injection protocol for BoNT-A&#xD;
      treatment is upon physicians' decision. All CD patients will undergo up to three evaluations&#xD;
      of motor and non-motor symptoms: before (baseline) and 1 month and 3 months after botulinum&#xD;
      toxin treatment. Both evaluations will be carried out under the same conditions. Motor&#xD;
      symptoms will be assessed in all CD using the Comprehensive Cervical Dystonia Rating scale&#xD;
      (CCDRS) (Comella et al, 2015). Non-motor symptoms including psychiatric, psychological and&#xD;
      sleep disorders will be investigated. Psychiatric symptoms will be assessed with CCDS,&#xD;
      Hamilton Rating Scale for Anxiety (HAM-A) and the Hamilton Rating Scale for Depression&#xD;
      (HAM-D); the psychological symptoms will be assessed with the demoralization scale (Kissane&#xD;
      et al, 2004) and the Italian Perceived Disability Scale (Innamorati et al,2009). Sleep&#xD;
      disorders will be investigated with the Pittisburg Sleep Quality Index (PSQI) (Buysse et al,&#xD;
      1989).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cervical dystonia (CD) is a focal dystonia, characterized by sustained muscle contractions of&#xD;
      the neck causing repetitive movements, or abnormal postures. The muscles' activation pattern&#xD;
      may lead to neck rotation (torticollis), flexion (anterocollis), extension (retrocollis), or&#xD;
      head tilt (laterocollis) or a combination of these. Patients with CD may also have head&#xD;
      tremor.&#xD;
&#xD;
      In addition to motor symptoms, CD patients may have non-motor features including psychiatric&#xD;
      disturbances, sleep difficulties, cognitive impairment and neck pain.&#xD;
&#xD;
      The first line of treatment for CD is botulinum toxin-A (BoNT-A) injection therapy&#xD;
      administered approximately at every 12 weeks. Several studies showed that one month after&#xD;
      BoNT-A treatment there is an improvement of motor symptoms in the majority of CD patients.&#xD;
      Conversely, regarding the effect of BoNT-A on non-motor symptoms previous studies in CD&#xD;
      focused only on the possible effect on depressive symptoms and on neck pain.&#xD;
&#xD;
      No study has so far investigated whether the treatment with BoNT-A may improve non-motor&#xD;
      symptoms in CD, including psychological aspects, such as demoralization and perceived&#xD;
      disability.&#xD;
&#xD;
      Main aim of this study is therefore to assess the effect of botulinum neurotoxin type A&#xD;
      (BoNT-A) treatment on motor and non-motor symptoms, including psychiatric and psychological&#xD;
      symptoms (anxiety, depression, demoralization, perceived disability) and sleep. To this aim&#xD;
      CD patients will be re-tested at 1 month and at 3 months after the treatment with BoNT-A.&#xD;
      Investigators will also assess a possible relationship between the improvements of motor&#xD;
      symptoms with that of non-motor symptoms at 1 month and at 3 months after BoNT-A treatment&#xD;
      and the frequency and severity of non-motor symptoms in a large population of CD patients.&#xD;
&#xD;
      To see whether non-motor symptoms in CD are the consequence of motor symptoms, investigators&#xD;
      will compare the severity of non-motor symptoms with the severity of motor symptoms, as well&#xD;
      as with the different clinical patterns of CD and with the presence or absence of head&#xD;
      tremor.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2020</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">February 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in depression scores from baseline to month 1 and 3</measure>
    <time_frame>From baseline to month 1 and 3 after treatment</time_frame>
    <description>Changes in the Hamilton Rating Scale for depression (HAM-D) before and after three months from treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in anxiety scores from baseline to month 1 and 3</measure>
    <time_frame>From baseline to month 1 and 3 after treatment</time_frame>
    <description>Changes in the Hamilton Rating Scale for anxiety (HAM-A) before and after three months from treatment</description>
  </primary_outcome>
  <enrollment type="Anticipated">43</enrollment>
  <condition>Dystonia, Focal</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>botulinum toxin A</intervention_name>
    <description>Intramuscolar injection of botulinum toxin in affected muscles</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with diagnosis of Cervical dystonia&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Cervical dystonia patients (primary dystonia).&#xD;
&#xD;
          -  BoNT-A na√Øve or pre-treated with any BoNT-A product.&#xD;
&#xD;
          -  Signed informed consent prior to participation in the study. If previously treated&#xD;
             with any BoNT-A, at least a 3-4 months interval between last injection and inclusion.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  - All secondary causes of dystonia (e.g. parkinsonian syndromes, or exposition of&#xD;
             dopamine receptor blocking drugs) will be excluded.&#xD;
&#xD;
          -  Major psychiatric disorders.&#xD;
&#xD;
          -  Sensitivity to BoNT-A or to its excipients&#xD;
&#xD;
          -  Other contraindications as given in the local SmPC for BoNT-A&#xD;
&#xD;
          -  Pregnant &amp; lactating women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Giovanni Fabbrini, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Depatment Human Neurosciences Sapienza University of Rome</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alfredo Berardelli, MD</last_name>
    <phone>+390649914700</phone>
    <email>alfredo.berardelli@uniroma1.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Human Neurosciences</name>
      <address>
        <city>Rome</city>
        <zip>00185</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giovanni Fabbrini, MD</last_name>
      <phone>+393386369901</phone>
      <email>giovanni.fabbrini@uniroma1.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <results_reference>
    <citation>Fabbrini G, Berardelli I, Moretti G, Pasquini M, Colosimo C, Berardelli A. Nonmotor symptoms in adult-onset focal dystonia: psychiatric abnormalities. Mov Disord. 2011 Aug 1;26(9):1765-6. doi: 10.1002/mds.23668. Epub 2011 Mar 25.</citation>
    <PMID>21442656</PMID>
  </results_reference>
  <results_reference>
    <citation>Berardelli I, Ferrazzano G, Pasquini M, Biondi M, Berardelli A, Fabbrini G. Clinical course of psychiatric disorders in patients with cervical dystonia. Psychiatry Res. 2015 Sep 30;229(1-2):583-5. doi: 10.1016/j.psychres.2015.07.076. Epub 2015 Jul 29.</citation>
    <PMID>26239770</PMID>
  </results_reference>
  <results_reference>
    <citation>Conte A, Berardelli I, Ferrazzano G, Pasquini M, Berardelli A, Fabbrini G. Non-motor symptoms in patients with adult-onset focal dystonia: Sensory and psychiatric disturbances. Parkinsonism Relat Disord. 2016 Jan;22 Suppl 1:S111-4. doi: 10.1016/j.parkreldis.2015.09.001. Epub 2015 Sep 3. Review.</citation>
    <PMID>26360238</PMID>
  </results_reference>
  <results_reference>
    <citation>Ferrazzano G, Berardelli I, Conte A, Suppa A, Fabbrini G, Berardelli A. Interoceptive sensitivity in patients with cervical dystonia. Parkinsonism Relat Disord. 2017 Nov;44:129-132. doi: 10.1016/j.parkreldis.2017.08.019. Epub 2017 Aug 16.</citation>
    <PMID>28827008</PMID>
  </results_reference>
  <results_reference>
    <citation>Ferrazzano G, Berardelli I, Conte A, Baione V, Concolato C, Belvisi D, Fabbrini G, Defazio G, Berardelli A. Motor and non-motor symptoms in blepharospasm: clinical and pathophysiological implications. J Neurol. 2019 Nov;266(11):2780-2785. doi: 10.1007/s00415-019-09484-w. Epub 2019 Jul 29.</citation>
    <PMID>31359200</PMID>
  </results_reference>
  <results_reference>
    <citation>Berardelli I, Ferrazzano G, Belvisi D, Pompili M, Fabbrini G. Psychiatric disorders in blepharospasm: A 10-year follow-up study. Psychiatry Res. 2020 Aug;290:113092. doi: 10.1016/j.psychres.2020.113092. Epub 2020 May 26.</citation>
    <PMID>32505028</PMID>
  </results_reference>
  <results_reference>
    <citation>Ferrazzano G, Berardelli I, Belvisi D, De Bartolo MI, Di Vita A, Conte A, Fabbrini G. Awareness of Dystonic Posture in Patients With Cervical Dystonia. Front Psychol. 2020 Jun 23;11:1434. doi: 10.3389/fpsyg.2020.01434. eCollection 2020.</citation>
    <PMID>32655462</PMID>
  </results_reference>
  <results_reference>
    <citation>Berardelli I, Ferrazzano G, Belvisi D, Baione V, Fabbrini G, Innamorati M, Berardelli A, Pompili M. Suicidal ideation, hopelessness, and affective temperament in patients with blepharospasm. Int J Psychiatry Clin Pract. 2020 Jul 15:1-6. doi: 10.1080/13651501.2020.1790613. [Epub ahead of print]</citation>
    <PMID>32669012</PMID>
  </results_reference>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 9, 2020</study_first_submitted>
  <study_first_submitted_qc>September 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 23, 2020</study_first_posted>
  <last_update_submitted>September 16, 2020</last_update_submitted>
  <last_update_submitted_qc>September 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Roma La Sapienza</investigator_affiliation>
    <investigator_full_name>Giovanni Fabbrini</investigator_full_name>
    <investigator_title>Full Professor of Neurology</investigator_title>
  </responsible_party>
  <keyword>depression</keyword>
  <keyword>anxiety</keyword>
  <keyword>sleep</keyword>
  <keyword>cognitive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dystonia</mesh_term>
    <mesh_term>Dystonic Disorders</mesh_term>
    <mesh_term>Torticollis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Single center study</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

